- Page 4:
ContentsEditorial GroupAcknowledgem
- Page 8 and 9:
AppendicesAppendix 1 - Nicotine Rep
- Page 10 and 11:
AcknowledgementsA huge number of pe
- Page 12 and 13:
Summary of Major changes in Therape
- Page 14 and 15:
On discharge• As the discharge pr
- Page 16:
Other examples• Sevredol 10 mg ta
- Page 19 and 20:
Antiplatelets and anticoagulants:In
- Page 21 and 22:
non-Formulary medicines, a complete
- Page 23 and 24:
Quick guide to using the handbookWh
- Page 25 and 26:
Sections1. Resuscitation and Anaphy
- Page 27 and 28:
Section 1Resuscitation and Anaphyla
- Page 29 and 30:
Continued from previous page2. Adre
- Page 31 and 32:
Peri-arrest ArrhythmiasGeneral advi
- Page 33 and 34:
Broad QRS - continuedNarrow QRS - c
- Page 35 and 36:
Guidelines on Blood TransfusionThis
- Page 37 and 38:
Management of Major Haemorrhage(See
- Page 39 and 40:
Hospital Specific Information on Ma
- Page 41 and 42:
Table continued from previous pageG
- Page 43 and 44:
Assessment / MonitoringAKI stage I
- Page 45 and 46:
Section 2Drug Overdose and Toxicity
- Page 47 and 48:
Treatment of Paracetamol OverdoseTh
- Page 49:
Management of paracetamol overdose
- Page 52 and 53: Lithium toxicityNormal range 0.4 -
- Page 54 and 55: Management of DyspepsiaGastrointest
- Page 57 and 58: Table continued from previous pageR
- Page 59 and 60: Management of Gastroduodenal Ulcers
- Page 61 and 62: Management of Upper Gastrointestina
- Page 63 and 64: Post endoscopy continuedb. Arrange
- Page 65 and 66: General management and treatment op
- Page 67 and 68: - SAAG can differentiate ascites re
- Page 69 and 70: General management and drug therapy
- Page 71 and 72: Drug therapy• Unless contraindica
- Page 73 and 74: Consider:• Serum caeruloplasmin,
- Page 75 and 76: Section 4Cardiovascular SystemCardi
- Page 77 and 78: Table 1 - Indicators of patients at
- Page 79 and 80: Continued from previous pageIf the
- Page 81 and 82: Diagnosis and Treatment of VenousTh
- Page 83 and 84: Wells Clinical score should be util
- Page 85 and 86: IV Drug Misusers• Given their cha
- Page 87 and 88: Drug therapy / treatment options co
- Page 89 and 90: RivaroxabanRivaroxaban is an oral d
- Page 91 and 92: Diagnosis of VTE in pregnancy• If
- Page 93 and 94: Referral of Patients to Anticoagula
- Page 95 and 96: Reversal of Anticoagulant TherapyIn
- Page 97 and 98: General management and drug therapy
- Page 99 and 100: Elective admissions - Risk Stratifi
- Page 101: Elective admissions - restarting an
- Page 105 and 106: Initial management of STEMI present
- Page 107 and 108: Interventional Cardiology Referral
- Page 109 and 110: Continued from previous pageCalcium
- Page 111 and 112: Table 1 - Antiplatelet dual therapy
- Page 113 and 114: Secondary Prevention of Coronary He
- Page 115 and 116: Atrial Fibrillation (AF) or Flutter
- Page 117 and 118: Atrial Fibrillation (AF) - Persiste
- Page 119 and 120: Prevention of stroke / thromboembol
- Page 121 and 122: Drugs for atrial fibrillationSee gu
- Page 123 and 124: Management of Acute Pulmonary Oedem
- Page 125 and 126: CPAP algorithmSpO 2< 90 % on high f
- Page 127 and 128: Management of Acute Stroke 1Present
- Page 129 and 130: Management of Acute Stroke 2The fir
- Page 131 and 132: • Reconsider potential indication
- Page 133 and 134: • Prescribe:Aspirin oral 300 mg l
- Page 135 and 136: Blood Pressure (BP)After the acute
- Page 137 and 138: Section 5Respiratory SystemRespirat
- Page 139 and 140: Interpretation of blood gasesFirst
- Page 141 and 142: Guidelines on Oxygen and OximetryGu
- Page 143 and 144: threatening attacks may not be dist
- Page 145 and 146: Continued from previous pageMONITOR
- Page 147 and 148: Drug therapy / treatment options co
- Page 149 and 150: Treatment optionsTreatment: immedia
- Page 151: Non-Invasive Ventilation (NIV) Prot
- Page 154 and 155:
Step 6 - Treatment failure• Indic
- Page 156 and 157:
• Anticoagulation (raised prothro
- Page 158 and 159:
Management of PneumoniaRespiratory
- Page 160 and 161:
Treatment options continuedDischarg
- Page 162 and 163:
Management of Spontaneous Pneumotho
- Page 164 and 165:
Treatment / drug therapy continuedI
- Page 166 and 167:
Treatment / drug therapy• Treatme
- Page 168 and 169:
General Principles of Acute Pain Ma
- Page 170:
Paracetamol IV continuedAdministrat
- Page 173 and 174:
Analgesics for acute pain - prescri
- Page 175:
Drug therapyThe table below is a ge
- Page 178 and 179:
Central Nervous SystemImmediate non
- Page 180 and 181:
Central Nervous SystemPharmacologic
- Page 182 and 183:
Management of DepressionN.B. MHRA h
- Page 184 and 185:
Continued from previous pageBaselin
- Page 186 and 187:
Vitamin Prophylaxis and Treatment o
- Page 188 and 189:
Management of Drug Misusers in Hosp
- Page 190 and 191:
Treatment options(N.B. All these me
- Page 192 and 193:
Crisis management prescribing for b
- Page 194 and 195:
Suspected SAHYESDoes the patient ha
- Page 196 and 197:
Guidelines for the Management of Pa
- Page 198 and 199:
SIGN 110. Early management of adult
- Page 200 and 201:
Patients with generalised tonic-clo
- Page 202 and 203:
Guideline for Phenytoin Dose Calcul
- Page 204 and 205:
Continued from previous pageN.B. Ta
- Page 206 and 207:
Parkinson’s Disease in Acute Care
- Page 208 and 209:
Central Nervous SystemPage 198
- Page 210 and 211:
Management of infectionsIntroductio
- Page 212 and 213:
Factors associated with CDI continu
- Page 214 and 215:
Antibiotic Allergy and Interactions
- Page 216 and 217:
Table 1 - Antibiotic IV to oral swi
- Page 218 and 219:
Table 1 - Alert AntibioticsInfectio
- Page 220 and 221:
Table 1 - Alert Antibiotics continu
- Page 222 and 223:
Sepsis Source Unknown (not immunoco
- Page 224 and 225:
Immunocompromised patients with fev
- Page 226 and 227:
Endocarditis• Take three sets of
- Page 228 and 229:
Guideline updated 08/11/13Urinary t
- Page 230 and 231:
InfectionsUTI in non-pregnant women
- Page 232 and 233:
InfectionsTable continued from prev
- Page 234 and 235:
Table continued from previous page
- Page 236 and 237:
Upper respiratory tract infectionsU
- Page 238 and 239:
Table continued from previous pageU
- Page 240 and 241:
Lower respiratory tract infections
- Page 242 and 243:
Pneumonia (continued from previous
- Page 244 and 245:
Pneumonia (continued from previous
- Page 247 and 248:
Table continued from previous pageI
- Page 249 and 250:
Management of suspected Clostridium
- Page 251 and 252:
Skin and soft tissue infections•
- Page 253 and 254:
Skin and soft tissue infections (co
- Page 255 and 256:
Bone and joint infection• Discuss
- Page 257 and 258:
Bacterial meningitis continuedBacte
- Page 259 and 260:
Brain abscess• Perform blood cult
- Page 261 and 262:
Viral infections (continued from pr
- Page 263 and 264:
Genito-urinary infections (continue
- Page 265 and 266:
HIV infection in hospital• Contac
- Page 267 and 268:
Outpatient Parenteral Antibiotic Th
- Page 269 and 270:
Surgical Antibiotic ProphylaxisThe
- Page 271 and 272:
Amikacin dosing guidelines (For pat
- Page 273 and 274:
Step 1 continued from previous page
- Page 275 and 276:
Step 3: Assess daily: the ongoing n
- Page 277 and 278:
Vancomycin maintenance intermittent
- Page 279 and 280:
Toxicity• Monitor creatinine dail
- Page 281 and 282:
Continued from previous pageStep 2:
- Page 283 and 284:
Teicoplanin dosing guidelines (For
- Page 285 and 286:
Section 9Endocrine SystemEndocrine
- Page 287 and 288:
Continued from previous page• 0.9
- Page 289 and 290:
Management of HyperglycaemicHyperos
- Page 291 and 292:
General management and drug therapy
- Page 293 and 294:
Management of Diabetes for People R
- Page 295 and 296:
Bolus feeding -1. The feed is divid
- Page 297 and 298:
Insulin sliding scale, continuedPot
- Page 299 and 300:
General management and drug therapy
- Page 301 and 302:
Types of Antidiabetic DrugsInjectab
- Page 303 and 304:
Management of Adrenal Insufficiency
- Page 305 and 306:
Section 9Electrolyte DisturbancesEl
- Page 308 and 309:
Management of Hypokalaemia (plasma
- Page 310 and 311:
Management of HypomagnesaemiaN.B. U
- Page 312 and 313:
Management of HypophosphataemiaIntr
- Page 314 and 315:
Management of HypercalcaemiaThis gu
- Page 316 and 317:
Management of HypocalcaemiaIntroduc
- Page 318 and 319:
Management of HypernatraemiaSerum N
- Page 320 and 321:
Management of GoutIntroductionGout
- Page 322 and 323:
Management of ArthritisIntroduction
- Page 324 and 325:
Treatment options continuedB. Disea
- Page 326 and 327:
Pain Management in Palliative CareP
- Page 328 and 329:
Subcutaneous analgesiaCalculate the
- Page 330 and 331:
Good prescribing points for transde
- Page 332 and 333:
Table continued from previous pageP
- Page 334 and 335:
Palliative Care - Last days of life
- Page 336 and 337:
Palliative CarePage 326
- Page 338 and 339:
Management of acute oncologicalcomp
- Page 340 and 341:
Continued from previous page• Pai
- Page 342 and 343:
Oncological EmergenciesTreatment /d
- Page 344 and 345:
Tumour Lysis SyndromeThis section d
- Page 346 and 347:
Malignant-related AscitesIntroducti
- Page 348 and 349:
Oncological EmergenciesPage 338
- Page 350 and 351:
AppendicesAppendix 1Nicotine Replac
- Page 352 and 353:
AppendicesAminophyllineIf intraveno
- Page 354 and 355:
AppendicesAppendix 3Therapeutic Dru
- Page 356 and 357:
AppendicesAppendix 4Mental Health L
- Page 358 and 359:
AppendicesAppendix 6Useful telephon
- Page 360 and 361:
AppendicesGlasgow Royal Infirmary (
- Page 362 and 363:
AppendicesSandyford Initiative (GUM
- Page 364 and 365:
IndexAAbbreviated Mental Test......
- Page 366 and 367:
Bites (human / animal)Treatment of
- Page 368 and 369:
ConstipationManagement of..........
- Page 370 and 371:
Gentamicin continuedInitial synergi
- Page 372 and 373:
InsulinIn DKA......................
- Page 374 and 375:
OlanzapineCautions / containdicatio
- Page 376 and 377:
Respiratory tract infections, treat
- Page 378 and 379:
Vancomycin continuedIn spontaneous
- Page 380 and 381:
Notes
- Page 382:
Notes